title: Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?
abstract: OBJECTIVE
  To correlate serum CA125 at relapse with survival in ovarian cancer patients who achieved a complete response after primary cytoreduction and paclitaxel- and platinum-based chemotherapy.
  
  
  METHODS
  The study was conducted in 104 patients.
  
  
  RESULTS
  The 25%, 50%, and 75% quantiles of CA125 levels at relapse were 46, 118, and 190 U/ml. By log-rank test, survival after recurrence was related to consolidation treatment (p = 0.046), platinum-free interval (PFI) (p < 0.000005), number of recurrence sites (p = 0.03), treatment at recurrence (p = 0.002), and serum CA125 taking 118 U/ml as cut-off (p = 0.013). On multivariate analysis, consolidation treatment (p = 0.007), PFI (p = 0.0001), treatment at recurrence (p = 0.01), and serum CA125 taking 118 U/ml as cut-off (p = 0.04) were independent prognostic variables for survival.
  
  
  CONCLUSIONS
  Serum CA125 at relapse was an independent prognostic variable. Patients with serum CA125 > 118 U/m had 1.943 higher risk of death than those with lower antigen value.
authors.forename: A
authors.initials: A
authors.lastname: Gadducci
authors.forename: M
authors.initials: M
authors.lastname: Notarnicola
authors.forename: A
authors.initials: A
authors.lastname: Menichetti
authors.forename: N
authors.initials: N
authors.lastname: Lanfredini
authors.forename: A
authors.initials: A
authors.lastname: Fanucchi
authors.forename: S
authors.initials: S
authors.lastname: Cosio
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000097:blood / Q000473:pathology / Q000628:therapy; D002288:Adenocarcinoma, Mucinous / Q000097:blood / Q000473:pathology / Q000628:therapy; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab / Q000008:administration & dosage; D018394:CA-125 Antigen / Q000097:blood*; D016190:Carboplatin / Q000008:administration & dosage; D002277:Carcinoma / Q000097:blood* / Q000473:pathology / Q000628:therapy; D018269:Carcinoma, Endometrioid / Q000097:blood / Q000473:pathology / Q000628:therapy; D015331:Cohort Studies; D065426:Cytoreduction Surgical Procedures; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000473:pathology; D009367:Neoplasm Staging; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000097:blood / Q000473:pathology / Q000628:therapy; D010051:Ovarian Neoplasms / Q000097:blood* / Q000473:pathology / Q000628:therapy; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D018394:CA-125 Antigen; D000068258:Bevacizumab; D015251:Epirubicin; D016190:Carboplatin; D017239:Paclitaxel